enhanced international prognostic index in japanese patients with diffuse large b-cell lymphoma

Clicks: 213
ID: 151338
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005); and their 5-year progression-free survival (PFS) was 76.8%, 78.6%, 63.7% and 58.3% (P=0.0722). The NCCN-IPI is a simple scale that uses conventional clinical factors, but did not reflect survival in our cohort. The NCCN-IPI may require further evaluation for different regions and ethnicities before adopting it for routine clinical use.
Reference Key
nakaya2016leukemiaenhanced Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Aya Nakaya;Shinya Fujita;Atsushi Satake;Takahisa Nakanishi;Yoshiko Azuma;Yukie Tsubokura;Masaaki Hotta;Hideaki Yoshimura;Kazuyoshi Ishii;Tomoki Ito;Shosaku Nomura
Journal urology annals
Year 2016
DOI
10.1016/j.lrr.2016.06.003
URL
http://www.sciencedirect.com/science/article/pii/S2213048916300140
Keywords
rituximab Oncology including cancer and carcinogens tumors albuminneoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.